Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.

Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease

Lopetuso, L. R.
;
2020

Abstract

Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.
File in questo prodotto:
File Dimensione Formato  
izz274.pdf

Solo gestori archivio

Descrizione: Editorial
Tipologia: PDF editoriale
Dimensione 86.62 kB
Formato Adobe PDF
86.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11564/725971
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact